Revista: | Memorias do Instituto Oswaldo Cruz |
Base de datos: | PERIÓDICA |
Número de sistema: | 000437055 |
ISSN: | 0074-0276 |
Autors: | Biembengut, Isis Venturi1 Souza, Tatiana de Arruda Campos Brasil de1 |
Institucions: | 1Fundacao Oswaldo Cruz, Instituto Carlos Chagas, Curitiba, Parana. Brasil |
Any: | 2020 |
Volum: | 115 |
País: | Brasil |
Idioma: | Inglés |
Tipo de documento: | Nota breve o noticia |
Enfoque: | Experimental, aplicado |
Resumen en inglés | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection depends on viral polyprotein processing, catalysed by the main proteinase (Mpro). The solution of the SARS-CoV-2 Mpro structure allowed the investigation of potential inhibitors. This work aims to provide first evidences of the applicability of commercially approved drugs to treat coronavirus disease-19 (COVID-19). We screened 4,334 compounds to found potential inhibitors of SARS-CoV-2 replication using an in silico approach. Our results evidenced the potential use of coagulation modifiers in COVID-19 treatment due to the structural similarity of SARS-CoV-2 Mpro and human coagulation factors thrombin and Factor Xa. Further in vitro and in vivo analysis are needed to corroborate these results |
Disciplines | Medicina |
Paraules clau: | Química farmacéutica, COVID-19, SARS-CoV-2, Proteasas, Coagulación |
Keyword: | Medicinal chemistry, Proteases, Coagulation, COVID-19, SARS-CoV-2 |
Text complet: | Texto completo (Ver HTML) Texto completo (Ver PDF) |